Zydus and Torrent's Bold Move in Diabetes Care

Zydus Lifesciences has entered into a strategic licensing and supply agreement with Torrent Pharmaceuticals to co-market Semaglutide Injection in India for the treatment of type 2 diabetes and chronic weight management in adults.

The agreement grants Torrent Pharma semi-exclusive rights to market the medication under its brand name, Sembolic, capitalizing on its robust presence in chronic therapy domains across the nation.

Under the terms, Torrent Pharma will pay an upfront licensing fee to Zydus, which is responsible for manufacturing the medication using an innovative prefilled cartridge system for reuse. This partnership highlights a significant advancement in diabetes care.